180 LIFE SCIENCES CORP (ATNF)

Company Profile

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California and currently employs 5 full-time employees. The company went IPO on 2017-06-07. The firm is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing research, and combination therapy. The firm's focus is a program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The firm has three product development platforms Anti-TNF platform, SCAs platform and a7nAChR platform. The Anti-TNF platform is focused on the fibrosis and anti-tumor necrosis factor (anti-TNF). The SCAs platform is focused on the drugs that are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). The a7nAChR platform, which is focused on the alpha 7 nicotinic acetylcholine receptor (a7nAChR). The company is conducting clinical trials only for certain indications under the anti-TNF platform. The firm is also undertaking preclinical research and development activities for the SCA and the a7nAChR platforms.

Company Info

180 LIFE SCIENCES CORP

3000 El Camino Real, Bldg 4, Ste 200

Palo Alto CALIFORNIA 10019

P: 16505070669

CEO: James N. Woody

Employees: 5

Website: https://180lifesciences.com/